Phaseline

Targets › ENVELOPE

ENVELOPE: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: the race on ENVELOPE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ANRS, Emerging Infectious Diseases3BNC117-LS
broadly neutralizing antibody against HIV-1 envelope protein
ENVELOPEPhase 2HIV/AIDS and InfectionsDec 2026

Conditions

HIV/AIDS and Infections (1)

Modalities

antibody (1)

Companies

ANRS, Emerging Infectious Diseases (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.